TAK-875 (fasiglifam) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, TAK-875 was withdrawn from phase III clinical trials due to drug-induced liver injury (DILI).
In this poster, we focus on:
- Investigating the mechanism behind the hepatotoxicity of TAK-875
- An in-depth understanding of the effect of TAK-875 on mitochondrial toxicity
- Understanding the impact of plasma protein binding
Read our poster to learn more about our research!
